Today: 30 June 2026
Browse Category

NASDAQ:IFRX 10 November 2025

InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx N.V. surged into today’s session after unveiling topline Phase 2a data for its oral C5aR inhibitor INF904 in hidradenitis suppurativa and chronic spontaneous urticaria, alongside filing its third‑quarter Form 6‑K showing €44.4 million of available funds and a cash runway into 2027. The company also set out next steps: a Phase 2b HS trial targeted to start in 2026 and continued partnering discussions to accelerate development across indications. HS:
10 November 2025
·

Stock Market Today

  • JPMorgan Chase Gets Zacks Rank Upgrade as Earnings Estimates Climb
    June 30, 2026, 1:31 PM EDT. Zacks upgraded JPMorgan Chase & Co. (JPM) to a #2 (Buy) rating after a rise in earnings estimates. The Zacks system looks only at sell-side analyst forecast changes to call stock moves. That upgrade signals better business trends for JPMorgan and may lift the shares. Institutional investors focus on earnings estimates when pricing stocks and often trade hard on new projections. Zacks Rank, backed by historical returns, is aimed at giving retail investors a way to track those estimate trends.
Go toTop